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Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs
withdrawal is much higher than that of surgical bleeding if they are continued. In secondary
prevention, aspirin is a lifelong therapy and should never be stopped. Clopidogrel is regarded
as mandatory until the coronary stents are fully endothelialized, which takes 3 months for bare
metal stents, but up to 1 yr for drug-eluting stents. Therefore, interruption of antiplatelet
therapy 10 days before surgery should be revised. After reviewing the data on the use of anti-
platelet drugs in cardiology and in surgery, we propose an algorithm for the management of
patients, based on the risk of myocardial ischaemia and death compared with that of bleeding,
for different types of surgery. Even if large prospective studies with a high degree of evidence
are still lacking on different antiplatelet regimens during non-cardiac surgery, we propose that,
apart from low coronary risk situations, patients on antiplatelet drugs should continue their
treatment throughout surgery, except when bleeding might occur in a closed space. A thera-
peutic bridge with shorter-acting antiplatelet drugs may be considered.
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Antiplatelet agents are prescribed very widely for primary
and secondary prevention of cardiovascular disease in
Western countries to decrease the incidence of acute
cerebro- and cardiovascular events. These events are tightly
linked to the instability of atheromatous plaques and to the
thrombogenicity of blood.77 For example, more than
two-thirds of the sudden cardiac events (acute coronary
syndrome or sudden cardiac death)36 126 and half of the
postoperative myocardial infarctions (MIs)26 64 93 94 are due
to the disruption and thrombosis of an unstable plaque.
These plaques are characterized by a large lipid core
covered by a thin cap; they are densely infiltrated by macro-
phages, with signs of active inflammation;59 and they
appear as moderate stenoses (,60%) on coronary angio-
gram. Multiple cellular, humoral, and neuro-vegetative trig-
gers may destabilize these plaques and lead to the
development of an occluding thrombus.94 Acute coronary
syndrome is linked with pro-inflammatory and pro-
thrombotic conditions that involve an increase in fibrino-
gen, C-reactive protein, and plasminogen activator
inhibitor.45 In the postoperative setting, the risk of acute
coronary syndrome is further aggravated by the augmented
release of endogenous catecholamines, increased platelet
adhesiveness, and decreased fibrinolysis, which are charac-
teristic of the acute phase reaction.15 62 93 It is, therefore,
understandable that antiplatelet agents are particularly
helpful when the thrombogenic risk is the highest.
Around 2 million patients undergo coronary dilatation
each year in Western countries,111 and more than 90% of
these percutaneous coronary interventions (PCIs) involve
the placement of intracoronary stents. This procedure
requires long-term treatment with antiplatelet agents,
which are mandatory for the success of coronary stents.
About 5% of patients who have undergone PCI will
undergo non-cardiac surgery within the first year after
stenting,121 and anaesthetists may often be confronted with
such patients.
Therefore, a new problem frequently encountered in
clinical anaesthesia is how to manage a patient on aspirin
and clopidogrel after a recent PCI who is to undergo a
potentially haemorrhagic procedure. The dilemma is
between the risk of increasing blood loss when continuing
the antiplatelet agents in the perioperative period and the
risk of coronary thrombosis if the drugs are stopped
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abruptly. Recent data suggest that the traditional attitude
of stopping the medication 10 days before surgery poses
considerable danger and requires revision.23 49 53 70 76 103
This review concentrates on the perioperative use of anti-
platelet agents in coronary artery disease (CAD) patients,
although antiplatelet agents are used in many other con-
ditions such as peripheral vascular disease, carotid artery
stenting, prevention of recurrent stroke, and MI, or in
primary prevention for patients with multiple cardiovascu-
lar risk factors, particularly in diabetes.97 It is intended to
be an additional contribution to a recent review in the
British Journal of Anaesthesia on coronary artery stents,48
but dealing more specifically with the use of antiplatelet
drugs in the perioperative setting.
Antiplatelet agents: pharmacology
Antiplatelet agents are classified into three categories:
acetylsalicylic acid, thienopyridines, and platelet glyco-
protein (GP) IIb/IIIa receptor antagonists. Statins will be
added to this list because one of their pleiomorphic effects
is a decrease in platelet aggregability.
Acetylsalicylic acid
Acetylsalicylic acid (aspirin) achieves a complete and irre-
versible blockade of platelet COX-1 at the usual dosage of
50–150 mg per day. For a normal adult, a daily dose
beyond 150 mg increases haemorrhagic risk without
increasing protection.87 The dose may be increased up to
325 mg in patients with increased bodyweight. The ability
of platelets to aggregate is partially restored within 4–5
days after stopping aspirin.40 In primary prevention,
aspirin is indicated when the 10-yr risk of vascular events
is more than 10%.97 In secondary prevention, aspirin
decreases the myocardial re-infarction rate by 30% and
subsequent stroke by 25%.6 41 Aspirin is a lifelong therapy
which should never be discontinued after a coronary or
cerebrovascular event.2 3 39 91 106 In the absence of (low-
molecular weight) heparin, up to 300 mg per day is not a
contra-indication to regional or neuraxial blockade.46
Thienopyridines
Clopidogrel (Plavixw; loading dose: 300 mg, daily dose:
75 mg) is the only platelet ADP-receptor antagonist used
clinically. It decreases the risk of MI in unstable angina by
18% and the risk of coronary stent thrombosis and recur-
rent stroke by 30%,71 111 126 but increases the risk of spon-
taneous haemorrhage by 38% (incidence 1–2%).23 71
Bleeding time increases to a maximum of 1.5- to three-
fold normal after 3–7 days of treatment.40 The half-life of
clopidogrel is short (4 h), but recovery from the drug is
long (7 days) because of irreversible platelet inhibition.122
As for aspirin, normalization of coagulation relies on the
release of new platelets into the circulation, not on the
disappearance of the drug from the plasma. Clopidogrel
is an absolute contra-indication to regional/neuraxial
blockade.34 47 96 116 If necessary, it should be stopped 5–7
days before operation.122 Clopidogrel can be a substitute for
aspirin in non-responders or in the case of allergic reac-
tions. A new substance, prasugrel (AZD6140), is to be
released shortly; it is expected to be more potent and
to elicit fewer non-responders than clopidogrel.50
Thienopyridines are often combined with aspirin (dual
antiplatelet therapy) for unstable coronary plaque or
during the re-endothelialization phase of coronary stents.
Unfortunately, 12–20% of patients do not respond to
aspirin, particularly women and patients with diabetes,
and 6–24% do not respond to clopidogrel.66 This wide
variation is due to the multiplicity of tests used to quantify
aspirin effects and to the absence of an efficient and
specific test for evaluating clopidogrel activity.61
Resistance to antiplatelet agents might explain the high
incidence of MI recurrence or stent thrombosis in some
patients. Some studies show that patients with recurrent
stent thrombosis have an impaired response to aspirin,
which is not overcome by additional treatment with clopi-
dogrel.123 Specific gene variants implicated in thrombosis
might have an impact on the efficiency of antiplatelet
agent strategies. For example, the effect of aspirin on
platelet function is modified by the GP-IIIa nucleotide
polymorphism P1A2. Patients who are heterozygous for
this gene keep a high platelet adhesiveness under aspirin
therapy, whereas adhesiveness is efficiently blunted in
homozygous patients at the same dosage.24 In the future,
pharmacogenomics may be able to provide tests for differ-
entiating responders from non-responders.
GP IIb/IIIa antagonists
Platelet GP IIb/IIIa receptor antagonists are used for the pre-
vention of immediate thrombosis of coronary stents and are
prescribed for 24–48 h after PCI.74 Abciximab (ReoProw)
exhibits high-affinity receptor binding, whereas tirofiban
(Aggrastatw) and eptifibatide (Integrilinw) have low-affinity,
competitive, dose-dependent pharmacodynamics.40 After
discontinuation of an infusion of abciximab, the receptor
occupancy decreases to approximately 70% in 12 h, bleed-
ing time, which is prolonged to .30 min during infusion,
decreases to 10–15 min,30 and effective platelet aggregabil-
ity is restored in 48 h, but residual receptor blockade can be
observed up to 7 days. Tirofiban has a plasma half-life of
only 2 h; at 4 h after stopping the infusion, platelet aggreg-
ability is already 50% of its normal value and bleeding time
returns to normal.58 The half-life of eptifibatide is 2.5 h;
within 6 h after stopping the infusion, platelet function
recovers to more than 50%.114
Statins
Statins are used widely for their ability to lower low-
density lipoprotein and for their anti-inflammatory effects.
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They also increase nitric oxide (NO) production and
decrease vascular smooth muscle proliferation,57 properties
which, respectively, diminish platelet aggregation, and
re-stenosis rate after PCI. Statins are associated with minor
muscle side-effects (weakness, myalgias, or cramps in
1–5% of the cases) and slight elevation of creatine-kinase;
the incidence of major rhabdomyolysis is very low (0.15
per 1 million prescriptions), but postoperative cases have
been reported.33 In a retrospective study of 2816 patients,
atorvastatin was shown to decrease cardiac morbidity and
mortality by 50% after non-cardiac surgery.89 A controlled
randomized trial on a small population (100 patients), with
treatment for 30 days before and 6 months after vascular
surgery, showed a decreased cardiac complication rate
from 26% (placebo group) to 8% (atorvastatin group).27
These results have been supported by a large retrospective
analysis of 780 591 patients, where in the 77 278 patients
(9.9%) who had preoperative treatment with a statin, the
surgical mortality was lowered by 40%.68 A recent
meta-analysis of 15 publications (223 010 patients)
suggests that statins are beneficial in cardiovascular
patients, where the mortality is reduced from 3.1% to
1.9% in cardiac surgery and from 6.1% to 1.7% in vascu-
lar surgery.43 This benefit is noticeable mainly in high-risk
cases and in long-term mortality (.4 yr), but the inci-
dence of postoperative MI is not modified. However, the
evidence of benefit is largely based on observational data
and not on controlled trials.55 Therefore, patients already
on statins should continue the treatment in the periopera-
tive period, but there is insufficient evidence to rec-
ommend the routine use of statins for patients other than
those with established CAD.
Percutaneous coronary revascularization
The immediate period after a PCI is a high-risk period
because the stenotic lesion is transformed into an unstable
area due to the rupture of its endothelial covering. When
patients undergo non-cardiac surgery during this early
period, the rate of MI and mortality (average 30% and
20–40%, respectively) is 5–10 times higher than that for
matched patients undergoing the same operation under
maximal medical therapy or after appropriate delay.53 90 92 103
There are no high level of evidence studies on the
optimal delays between revascularization and non-cardiac
surgery. Therefore, recommendations are based on pathol-
ogy reports,38 60 117 expert opinion,1 3 91 106 and manu-
facturer advice, to estimate the time to complete
re-endothelialization of the coronary vessel. During this
period, a dual antiplatelet therapy consisting of aspirin and
clopidogrel is mandatory.2 106 It is usually accepted that
the duration of this dual treatment is 4–6 weeks after bare
metal stents (BMS), 3 months after sirolimus drug-eluting
stents (DES) (CypherTM), 6 months after paclitaxel DES
(TaxusTM AchieveTM, V-flexTM, CoStarTM), and 3–6
months for the second generation DES with zotarolimus
(EndeavorTM) or everolimus (Xience VTM).1 2 5 91 101 106
However, recent data (discussed later) tend to indicate that
DES are extremely dependent on the administration of clo-
pidogrel and that clopidogrel should be continued for 1 yr
after all types of DES, despite the increased risk of bleed-
ing. The updated AHA/ACC Science Advisory and the
Society of Cardiovascular Angiography DES Task Force
recommend 12 months of dual antiplatelet therapy after
DES, and postponement of all elective operations during
this period39 44 106 (Table 1). Aspirin is a lifelong treat-
ment and should never be interrupted whichever type of
stent is used.3 5 39 91
The usefulness of a dual antiplatelet therapy was
demonstrated by the PCI-Cure study of 2658 patients with
acute coronary syndrome undergoing PCI. Patients were
randomly assigned to a 1 yr treatment with clopidogrel
and aspirin or placebo and aspirin. In this study, an overall
31% reduction (P¼0.002) of cardiovascular mortality or
MI rate was observed in the clopidogrel group (Fig. 1).71
The difference between both groups appears during the
first 3 months, and stays constant or slightly increasing up
to 12 months. This raises the question of the usefulness of
clopidogrel beyond 1 yr. The CHARISMA study13 tried to
answer this question with 15 603 high-risk cardiovascular
patients randomly assigned to receive clopidogrel and
aspirin or placebo and aspirin, followed for a median
Table 1 Duration of antiplatelet therapy and recommended delays for
non-cardiac surgery after PCI
Dilatation without stenting: 2–4 weeks
Surgery postponed for 2–4 weeks (vital surgery only)
PCI and BMS: 4–6 weeks
Vital surgery postponed for 6 weeks
Elective surgery postponed for 3 months
PCI and DES: 12 months
Elective surgery postponed for 12 months
Aspirin: lifelong therapy, whichever is the revascularization technique
Fig 1 Twelve- month outcome of patients with stents receiving
clopidogrel or not (reproduced with permission from Mehta71).
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duration of 28 months. Similar rates of MI, stroke, or
cardiovascular death in both groups indicated that clopido-
grel plus aspirin was not more effective than aspirin alone
as primary prevention. Moreover, the rate of severe spon-
taneous bleeding was increased (2.1% vs 1.3%). In second-
ary prevention, a small 12% reduction in relative risk was
observed in the clopidogrel group, but also with a slight
increase in the bleeding risk. These data seemed to support
the use of clopidogrel for 1 yr only after PCI or a cardio-
vascular event, except in some particularly unstable cases.
New problems with DES
In late 2006, new findings were published concerning the
possible increased rate of late thrombosis with DES. It is
essential for the anaesthetist to be aware of the recent con-
troversies in cardiology because they have a direct impact
on decisions concerning the perioperative management of
stented patients. In the BASKET trial,88 746 non-selected
patients, randomly assigned to BMS or DES and surviving
6 months without major events, were followed for a
further year after discontinuation of clopidogrel at 6
months. The 18-month rate of re-stenosis was lower in
DES compared with BMS (4.5% vs 8.7%, OR 0.51), but
the 18-month rate of cardiac death or MI was not different
between DES and BMS patients. However, after the dis-
continuation of clopidogrel (between months 7 and 18),
these events occurred in 4.9% after DES compared with
1.3% after BMS (P¼0.01). The DES thrombosis-related
events had a mortality rate of 19%. In addition, an obser-
vational study on 4666 patients (3165 BMS and 1501
DES) taking clopidogrel for 6 months28 showed that the
individuals with DES still taking the drug after 24 months
had a composite rate of death or MI of 3.1%, whereas
those who stopped clopidogrel at 6 months had a compo-
site rate of 7.2% (P¼0.02) (Fig. 2). In patients with BMS,
there were no differences in death or MI rate with or
without long-term clopidogrel treatment. In the recent
Swedish Coronary Angiography and Angioplasty Registry
(6033 patients with DES and 13 738 patients with BMS),
the 13.7% reduction in composite rate of death and MI
among DES-treated patients in the first 6 months is offset
by a 12.7% increase in events in this group during the fol-
lowing year,63 giving an adjusted relative risk of death
between 6 months and 3 yr 30% higher in DES patients.
A meta-analysis involving 8221 patients80 seems to indi-
cate that not only cardiac mortality is increased among
DES compared with BMS patients, but also non-cardiac
mortality (OR 1.6–2.14), mainly due to an over-
representation of tumours in the patients with sirolimus-
eluting stents. Another intriguing observation is an
impaired collateral function with DES,72 where despite
equal stenosis severity and follow-up duration, collateral
flow index is diminished in DES compared with BMS
patients (P¼0.005), and the rate of collaterals insufficient
to prevent ischaemia during occlusion is higher in DES
compared with BMS (P¼0.001). Whether sirolimus-DES
or paclitaxel-DES are more prone to late thrombosis is still
controversial,9 25 44 105 but the mortality with both types of
DES is increased, at a rate of 0.6% yr21.19 25 51 88 Other
meta-analyses of recent clinical trials have shown slightly
conflicting results. Although some find a consistent trend
towards more frequent death and Q-wave MI at late
follow-up with DES,19 112 others tend to show that late
stent thromboses and death occur in BMS and DES,102 but
are more frequent with DES in diabetics.108 This raises a
difficult question about the replacement of BMS by DES:
are we trading early re-stenosis with BMS for late throm-
bosis with DES?104 In other words, are we trading a rela-
tively benign but frequent event (12–20% at 12 months)
for a rarer event (incidence 0.8–3%), but with a much
higher mortality (19–45%)?25 49 84 88 Numerically, this
means that for each 100 DES implanted, five re-stenoses
are prevented at 6 months, but three deaths or MIs occur
by 18 months.51 88 Part of the problem might be linked to
off-label indications for DES, which are normally indi-
cated for intermediate lesions, medium-sized vessels
(,3.5 mm), and short stenosis (,30 mm).75 Despite the
manufacturer recommendations, up to 60% of DES are
implanted in proximal, long, or bifurcated lesions, and
some studies suggest that adverse outcomes are more
frequent when DES are implanted outside the terms of
the licence.9 44 88 105
Withdrawal of antiplatelet agents
The fear of excessive bleeding leads to the generally
accepted policy of withdrawing antiplatelet agents 7–10
days before a surgical or endoscopic procedure. Knowing
the efficacy of these drugs in preventing coronary
stent thrombosis and MI, this raises an important question
regarding the safety of interrupting antiplatelet therapy.
Fig 2 Twenty-four month outcome of patients with BMS and DES, with
or without clopidogrel (reproduced with permission from Eisenstein28).
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Acute withdrawal of antiplatelet agents produces a dele-
terious rebound effect; pro-thrombotic effects overcome
the physiological balance. Excessive thromboxane A2
activity and decreased fibrinolysis have been noted on
stopping aspirin.12 31 120 In a study of 2229 patients with
DES and a thrombosis rate of 1.5% during the first year,
premature clopidogrel discontinuation was the most signifi-
cant independent predictor of stent thrombosis, with a
hazard ratio of 57.13 (P,0.001) and a mortality rate
linked to stent thrombosis of 45%.49 Patency of DES is
particularly dependent on clopidogrel during the first year.
Two-thirds of the late DES thromboses were linked to
stopping antiplatelet drugs.84 Compared with patients who
have taken the drug continuously, patients who stopped
clopidogrel during the first month after PCI are 10 times
more likely to die (7.5% and 0.7%, P,0.0001) or to be
re-hospitalized (23% and 14%, P¼0.08) during the next
11 months.109 In the BASKET trial, the MI and death
rates 7–18 months after cessation of clopidogrel were
more than doubled with DES compared with BMS (4.9%
and 1.3%, adjusted hazard ratio 2.2, P¼0.03).88 During
the year after discontinuation of clopidogrel, patients with
DES had a 38% higher rate of MI or death than with BMS
(P¼0.03).19 Antiplatelet drug withdrawal is even more
dangerous in the perioperative period. Stopping clopido-
grel to allow major surgery during the first 3 weeks after
PCI and stenting leads to mortalities ranging from 30%32
up to 86%.103 These data reinforce the need to maintain
full antiplatelet therapy in the perioperative period,
particularly for DES, even if the time from PCI is rela-
tively long.
The interruption of aspirin alone is also risky and may
lead to stent thrombosis even more than 1 yr after PCI and
DES.70 76 Acute coronary syndrome, leading to MI or
death, in patients who have stopped aspirin within the pre-
vious 3 weeks occurs at twice the rate of that for patients
who continued antiplatelet therapy.23 A meta-analysis of
50 279 patients for secondary prevention for CAD showed
that the cardiac complication rate was three times higher
after aspirin withdrawal (OR 3.14, P¼0.0001).14 This risk
was even higher in patients with coronary stents (OR
89.78). The delay between stopping aspirin and thrombotic
events averages 10.6 days (8.5 days for coronary symp-
toms and 14.3 days for cerebral vascular accidents).14 18
These data support the continuation of aspirin periopera-
tively. When aspirin is withdrawn for situations such as
intracranial neurosurgery, the interruption should be for a
maximum of 5–7 days, and the treatment resumed as soon
as possible after surgery (within 12–24 h). However, in
patients with stents, aspirin must never be stopped.5 39 44
The acute cessation of statins is also harmful, because
it is accompanied by a rebound phenomenon and an
increased platelet aggregability. Statin therapy withdra-
wal within 24 h of acute coronary syndrome is associ-
ated with a significant increase in cardiac risk (adjusted
hazard ratio 2.93, P¼0.005), independent of cholesterol
levels.42 It is, therefore, safer to continue statin therapy
throughout the surgical period, despite the small risk of
rhabdomyolysis.43 57
Stopping antiplatelet agents is the major independent
predictor for late stent thrombosis, but other factors have a
high predictive value for thrombotic events, including
stenting of small vessels, multiple lesions, long stents,
ostial or bifurcation lesions, suboptimal stent result, low
ejection fraction, advanced age, renal failure, and dia-
betes.5 39 In these situations, the advice is to maintain
long-term dual antiplatelet therapy. Stent thrombosis is
characterized by high mortality rates (19–45%)32 49 51 84 88
because it corresponds to an abrupt interruption of the
blood flow in a high-output vessel and the involved myo-
cardium has poor collaterals and is not pre-conditioned by
previous recurrent ischaemic episodes. DES tend to inhibit
collateral growth.72 With an average mortality of one for
every three cases, stent thrombosis is an extremely danger-
ous event. In a surgical setting, the risk is further increased
(up to 85%)103 by the cardiac complication rate specific to
the type of surgery and by the postoperative phase of
platelet hyper-aggregability and decreased fibrinolysis.
This clearly suggests that only exceptional situations can
justify stopping antiplatelet agents in these patients.
Haemorrhagic risks
If the thrombotic risk at withdrawal of antiplatelet agents
is high, what is the danger of surgery under continuous
antiplatelet therapy? Apart from surgery, the rate of severe
spontaneous bleeding recorded in various trials is
increased in patients taking dual therapy compared with
those on aspirin alone; 0.7–1.13% (37% increase in rela-
tive risk) in the ATC trial6 and 2.7–3.7% (27% increase in
relative risk) in the CURE trial.126 Unfortunately, studies
on intraoperative haemorrhagic risk of antiplatelet therapy,
although numerous, are usually statistically underpowered
and there are few if any large prospective randomized
studies. These have been carried out mainly in orthopae-
dics (hip arthroplasty) and cardiac surgery (CABG).
However, analysis reveals interesting facts about the
impact of aspirin and clopidogrel on surgical bleeding.
Patients on aspirin
A large review and meta-analysis of 474 studies on the
impact of low-dose aspirin on surgical blood loss showed
that patients on aspirin alone have an average intraopera-
tive haemorrhagic risk increased by a factor of 1.5,
without an increase in surgical mortality or morbidity.18
Despite a modest rise in bleeding rate, there were no
differences in surgical complications or outcome linked to
haemorrhage in most procedures such as dental, ophthal-
mological, visceral and minor general surgery, endosco-
pies, biopsies, and dialysis catheter insertion. In vascular
surgery, the increase in bleeding complications was only
Chassot et al.
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2.46%.78 In orthopaedics, the data are less clear, with
studies showing an increased rate of bleeding and transfu-
sion in hip arthroplasty,82 but not in osteosynthesis of
femoral neck fractures,69 spinal instrumentation, or multi-
level fusion surgery.81 Where there was an increased blood
loss, the average transfusion rate was increased by a factor
of 1.5, mainly due to oozing from bone and surrounding
tissues. Bleeding threatening vision did not occur in the
studies in ophthalmology.18 52 Local haemostasis measures
sufficiently controlled bleeding in oral surgery.107 118
Although aspirin increases bleeding by approximately 20–
30%, surgeons could not differentiate patients on aspirin
from patients on placebo just from surgical bleeding.67
Aspirin seems to be associated with a rise in bleeding
rate only in specific procedures. In cardiac surgery with car-
diopulmonary bypass, a review of 50 studies revealed an
average increase in bleeding of 300 ml per patient.11 After
tonsillectomy, the re-operation rate for postoperative haem-
orrhage was increased 7.2 times in an aspirin group com-
pared with an acetaminophen group.110 During transurethral
prostatectomy, the blood transfusion rate was increased by a
factor of 2.7 in patients on aspirin compared with control
groups,115 and importantly, there were two fatalities in this
series. However, the new technique of photoselective
vaporization with the potassium-titanyl-phosphate (KTP)
laser for endoscopic prostatectomy may decrease haemor-
rhagic complications in these patients.100 In intracranial
neurosurgery, aspirin has been involved in an increased risk
of postoperative intracerebral haematoma. In some cases, it
has been a contributing factor to the fatal outcome.85
Patients on dual therapy (aspirin and clopidogrel)
It would be expected that the addition of clopidogrel to
aspirin would increase surgical haemorrhage. Blood loss is
effectively increased on average by 30–50%, but most of
the studies have been conducted in cardiac surgery with
full intraoperative heparinization for cardiopulmonary
bypass. Clopidogrel intake during the last 4 days before
CABG has been shown to be an independent predictor of
re-operation for control of haemorrhage (OR 4.9, 95% Cl
2.63–8.97),54 (OR 6.9, 95% Cl 1.6–30)125 transfusions
(OR 4.22, 95% Cl 1.79–9.95),22 and length of stay in the
intensive care unit (OR 3.14, 95% Cl 1.40–7.04).22
Nevertheless, surgical outcomes and operative mortality
were not different from usual practice.54
There are fewer studies of the effect of clopidogrel in
non-cardiac surgery. In patients undergoing vascular,
orthopaedic, and visceral surgery after coronary stent
implantation, the transfusion rate was 38.5% in controls
and 42.6% in patients taking dual antiplatelet therapy124
(NS). After trans-bronchial biopsy, the bleeding rate is
very high (89%) in patients taking clopidogrel compared
with patients not on antiplatelet treatment (3.4%), but no
patient required transfusion and each case was controlled
by the endoscopic route.29 Case reports and small clinical
series in visceral and vascular surgery have shown a mod-
erate increase in surgical blood loss and transfusion rate,
but not in morbidity, mortality, or surgical outcome.
However, diffuse bleeding and tissue oozing where direct
surgical haemostasis is difficult may lead to delayed blood
loss during the first postoperative days. In oral surgery and
dentistry, there was no increased risk of haemorrhagic
complications in patients taking clopidogrel.39 107 In neu-
rosurgery, a short communication has recently described
seven patients who developed fatal intracerebral haemor-
rhage associated with neuro-interventional procedures and
the use of clopidogrel and the anti-GP IIb/IIIa, abcixi-
mab.95 It appears, therefore, that the continued use of clo-
pidogrel during the perioperative period increases the
surgical bleeding and the transfusion rate probably by a
factor of 50% but not the morbidity or the mortality, with
the exception of intracranial surgery.
Withdrawing or continuing antiplatelet
agents: the risks in balance
This question was already raised in the recent review in
the British Journal of Anaesthesia.48 Clinicians like to
receive clear-cut answers when they are confronted with
difficult situations. Therefore, we would like to present the
arguments balancing the risks of increased surgical blood
loss by continuing the antiplatelet drugs during the peri-
operative period and the risks of acute coronary syndrome
if they are withdrawn before the procedure.
On one hand are the risks of maintaining the antiplatelet
drugs.21
† Average increase in surgical blood loss of 2.5–20%
with aspirin, or 30–50% with aspirin and clopidogrel;
no increase in surgical mortality linked to this increased
bleeding, except during intracranial surgery, but
occasional increase in surgical complications.
† Average increase of 30% in transfusion rate; however,
complication rate of red blood cell transfusion is only
0.4% (all types of complications included),73 and mortality
linked directly to massive surgical blood loss is 3%.56
† The incidence of ischaemic events is probably similar to
the rate observed in patients with stable CAD; depending
on the type of procedure, the rate of non-fatal MI is
2–6% and the cardiac mortality is 1–5%.1 20
On the other hand are the risks of withdrawing the antipla-
telet agents.
† Rebound effect with increased platelet adhesiveness;120
simultaneously, the systemic inflammatory syndrome
and the acute phase reaction to surgery increase platelet
adhesiveness and decrease fibrinolysis;48 93 also, some
pathologies, such as carcinoma and diabetes, are
accompanied by hyper-coagulability.
† Doubled infarction and death rates in acute coronary
syndrome.23
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† During the re-endothelialization phase of coronary
stents, the average postoperative MI rate due to stent
thrombosis is 35%; the average mortality of stent
thrombosis is 20–40%,32 49 53 up to 85% in one post-
operative study;103 therefore, the perioperative cardiac
death rate is increased 5–10 times.
† First-generation DES are highly dependent on antiplate-
let agents during the first year after PCI.28 49 70 84 88
† Emergency PCI for revascularization of a thrombosed
coronary vessel during the early postoperative period is
more difficult and associated with a greater risk than
red blood cell transfusions and surgical haemostasis
during the operation. Thrombolysis and abciximab are
not an option in the immediate postoperative period
because of the risk of catastrophic bleeding.
It appears, therefore, that the risks of withdrawing the
patients from antiplatelet agents in the perioperative period
are generally higher than those of maintaining this vital
medication. Although each case must be managed on an
individual basis by the anaesthetist together with the
cardiologist and the surgeon, it is necessary to modify the
approach of withdrawing patients from all antiplatelet
agents 7–10 days before surgery, except when bleeding
might occur in a closed cavity.
Possible approaches
Pending large prospective studies with a high degree of
evidence on different antiplatelet agents regimens during
non-cardiac surgery, there is a wide diversity of practice
for patients on antiplatelet drugs. However, we would like
to propose a general approach based on the most recent
data, even if they are mainly based on research in
cardiology.
Proposed algorithm
The preoperative evaluation of patients on antiplatelet
therapy is presented in an algorithm we use in our insti-
tutions (Table 2, Fig. 3).21 In our opinion, this algorithm is
helpful for guiding the clinician through the, frequently
difficult, bedside decisions. Aspirin is a lifelong therapy
and should never be stopped before surgery when pre-
scribed as a secondary prevention after stroke, angina, MI,
or any type of revascularization (CABG, simple coronary
dilatation, PCI with any type of stent). However, when
prescribed as primary prevention, there are no studies indi-
cating that interruption might be harmful. Aspirin as
primary prevention may, therefore, be safely withdrawn
but no more than 7 days before surgery.
If clopidogrel is prescribed for an unstable angina or
during the re-endothelialization of a stent, it should not be
stopped before a non-cardiac procedure. This period lasts
at minimum 2–4 weeks after simple dilatation, 6 weeks
after BMS, 12 months after DES, and may even be pro-
longed beyond 1 yr in high-risk DES, such as long (.36
mm) and proximal stents, multiple stent implantation,
overlapping stents, stents in chronic total occlusions, small
vessels, or bifurcated lesions.5 High-risk situations also
include patients with a history of stent thrombosis, low
ejection fraction, diabetes, and carcinomas (possible
Table 2 Proposed scheme for management of patients taking antiplatelet therapy and requiring surgery. MI, myocardial infarction; CABG, coronary artery
bypass graft; PCI, percutaneous coronary intervention; BMS, bare metal stent; DES, drug-eluting stent; EF, ejection fraction
Surgical haemorrhagic risk Cerebro- and cardiovascular risk
Low Intermediate High
.6 months after MI, PCI,
BMS, CABG, stroke .12
months if complications
6–24 weeks after MI, PCIþBMS,
CABG, or stroke (Ø complication);
.12 months after DES; high-risk
stents (long, proximal, multiple,
overlapping, small vessels,
bifurcation); low EF, diabetes
,6 weeks after MI, PCI, BMS,
CABG; ,6 months after same if
complications; ,12 months after
high-risk DES; ,2 weeks after
stroke
Low risk
Transfusion normally not required;
peripheral, plastic, and general surgery,
biopsies; minor orthopaedic, ENT, and
general surgery; endoscopy; eye
anterior chamber; dental extraction and
surgery
Elective surgery: OK;
maintain aspirin
Elective surgery: OK; maintain aspirin,
clopidogrel (if prescribed)
Elective surgery: postpone; vital or
emergency surgery: OK; maintain
aspirin and clopidogrel
Intermediate risk
Transfusions frequently required;
visceral surgery; cardiovascular
surgery; major orthopaedic, ENT,
reconstructive surgery; endoscopic
urology
Elective surgery: OK;
maintain aspirin
Elective surgery: postpone; surgery
absolutely required: OK; maintain
aspirin, clopidogrel (if prescribed)
Elective surgery: postpone; vital or
emergency surgery: OK; maintain
aspirin and clopidogrel
High risk
Possible bleeding in a closed space;
intracranial neurosurgery; spinal canal
surgery; eye posterior chamber surgery
Elective surgery: OK;
maintain statin; withdraw
aspirin (maximum 7 days)
Elective surgery: postpone; surgery
absolutely required: OK; maintain
aspirin, or replace aspirin by
ibuprofen; stop clopidogrel
OK only for vital or emergency
surgery; maintain aspirin Bridge
with tirofiban/eptifibatide and
heparin
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hypercoagulability due to paraneoplasic syndromes). In
low-risk situations, it is possible to discontinue clopidogrel
for 1 week, but not aspirin. Low-risk situations include
patients more than 3 months after BMS, stroke, uncompli-
cated MI, or PCI without stenting. Present clinical data
tend to suggest that DES are probably never low-risk.
There is no evidence that patients who have completed
their clopidogrel treatment and are symptom-free after dis-
continuation should be restarted on dual therapy because
of surgery. However, patients still on dual antiplatelet
therapy during the re-endothelialization period after coron-
ary stenting should be operated on without interrupting
treatment. This statement applies to thoracic, abdominal,
vascular, orthopaedic, and superficial general surgery, and
to endoscopies and biopsies. Patients on clopidogrel
planned for an endoscopic urologic procedure should be
transferred to a centre equipped with the new KTP laser
technology instead of discontinuing antiplatelet agents for
transurethral prostatectomy. In ENT, oral surgery, and den-
tistry, it is possible to perform all types of procedures
while on low-dose aspirin treatment. In the case of dual
therapy, most of the current surgical procedures can be
safely undertaken. However, operations traditionally
associated with excessive blood loss should be postponed
unless vital. In ophthalmology, extra-ocular and anterior
chamber surgery can be conducted during dual antiplatelet
therapy, but not posterior chamber procedures, which
require the cessation of clopidogrel (but not aspirin). For
elective procedures, it is safer to postpone surgery until
clopidogrel can be withdrawn without risk. Only vital or
emergency surgery should be performed on full antiplate-
let therapy. After the operation, antiplatelet agents should
be resumed within the first 12–24 h.48
In closed spaces, such as intracranial surgery, spinal
surgery in the medullary canal, and surgery of the pos-
terior chamber of the eye, even a small postoperative
haemorrhage can have disastrous consequences.
Extracranial neurosurgery such as hernial disc repair can
be performed without stopping antiplatelet agents.
Therefore, the approach adopted in our institutions is to
leave aspirin but withdraw clopidogrel 7 days47 before
intracranial surgery, medullary surgery, and posterior
chamber ophthalmic surgery. In these cases, a ‘bridge’
with tirofiban or eptifibatide and heparin may be an option
(discussed later). This approach is not based on any con-
trolled prospective study, but may be viewed as a compro-
mise between platelet half-life, thrombotic risk, and
haemorrhagic risk, and it may be an option for operations
associated with excessive blood loss. Treatment must be
resumed as soon as possible after surgery with a loading
dose of 300 mg clopidogrel.5 48 In stereotaxic intracranial
procedures, aspirin should also be stopped, but it is more
reasonable to postpone this type of procedure until the
patient can safely stop all antiplatelet medication. Thus,
Fig 3 Algorithm for preoperative management of patients under antiplatelet therapy. MI, myocardial infarction; ACS, acute coronary syndrome; PAD,
peripheral arterial disease; PCI, percutaneous coronary intervention; BMS, bare metal stent; DES, drug eluting stent. *High-risk stents: long (.36 mm),
proximal, overlapping, or multiple stents implantation, stents in chronic total occlusions, stents in small vessels or bifurcated lesions. **Examples of
low-risk situations: .3 months after BMS, stroke, uncomplicated MI, PCI without stenting. ***Risk of bleeding in closed space: intracranial
neurosurgery, intra-medullary canal surgery, posterior eye chamber ophthalmic surgery. In these situations, the risk/benefit ratio of upholding vs
withdrawing aspirin must be evaluated for each case individually; in case of aspirin upholding, early postoperative re-institution is important.
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the presence of DES may be a contra-indication to stereo-
taxic procedures, since stopping aspirin is too dangerous.
The problem of regional and neuraxial blockade
Clopidogrel with aspirin during the week preceding an
operation is an accepted contra-indication to any form of
regional anaesthesia (RA).34 47 96 Spinal haematoma has
been described during clopidogrel treatment,113 but the
precise risk of spinal or epidural haematoma with dual
antiplatelet therapy is unknown.116 Anaesthetists may be
tempted to interrupt antiplatelet drugs on the assumption
that neuraxial blockade is safer than general anaesthesia in
a patient with CAD. However, only a high thoracic epi-
dural blockade (.T6 level) can produce cardiac sympatho-
lysis which increases coronary blood flow, decreases
myocardial O2 consumption (mVO2),
83 and may reduce
the incidence of postoperative MI linked to tight stenoses
and DO2/VO2 imbalance.
10 96 In a meta-analysis of 11 ran-
domized trials (1173 patients), neuraxial blockade at levels
below T6, alone or in combination with general anaesthe-
sia, did not significantly reduce the cardiac risk,86 or mor-
tality and infarction rate.10 In abdominal vascular surgery,
one study showed a decrease in cardiac complication rate
with combined anaesthesia compared with general anaes-
thesia (10:18%), but only in a subgroup of high-risk
patients undergoing long operations.86 One can argue that
RA might reduce the intensity of the acute phase reaction
linked to surgery, and therefore decrease the risk of throm-
bosis on unstable plaques, but this has not yet been
demonstrated.
High thoracic epidural anaesthesia decreases cardiac
morbidity by 40%,10 83 but stopping clopidogrel in the
case of unstable plaques or uncovered stents increases
infarction and death rates 5–10 times. To the best of our
knowledge, the protective effect of antiplatelet agents is
more efficacious than the effects of RA on arterial throm-
bosis and on the reduction of MI and cardiac death rates.
Moreover, the intraoperative sympatholysis of epidural
anaesthesia can be achieved with agents such as
b-blockers, a2-agonists, and higher dosages of opioids
given i.v. The price to pay for optimal protection against
acute coronary ischaemia may be a poorer quality of post-
operative analgesia and comfort for the patient without
epidural. We conclude that the risk/benefit ratio of pre-
operative withdrawal of antiplatelet drugs in order to
perform a regional or neuraxial blockade is not justified.
Platelet transfusion and antagonism
As the effects of antiplatelet agents are not reversible by
other drugs, fresh platelets are the only way to re-establish
a normal coagulation process. Haemostatis requires that at
least 50% of the circulating platelets have a normal func-
tion. The recommendations concerning platelet transfu-
sions have been presented in guidelines.48 99 However, the
activity of new platelets may be inhibited by drug present
in the circulation. The half-life of clopidogrel is 4 h and
its plasma level is close to zero after 12 h (three
half-lives). Therefore, beyond 6–8 h after the last intake,
the transfused platelets will not be significantly inhibited
by the substance, whereas the patient’s platelets are still
blocked by an irreversible effect. In emergency situations
or in the case of major bleeding, therefore, haemostasis
can be restored by administration of fresh platelets within
a few hours of the last clopidogrel intake. After discon-
tinuation of abciximab (ReoProw), effective platelet
aggregability is restored in 48 h, when ,50% of the recep-
tors are blocked.30 40 Platelet transfusions are mandatory
within 48 h after abciximab, even if some of the fresh
thrombocytes will be blocked by the residual circulating
levels of the drug. The plasma half-life of tirofiban
(Aggrastatw) and eptifibatid (Integrilinw) is close to 2 h.
Around 6 h after administration of these drugs, platelet
function returns to 60–90% of normal and bleeding time
is prolonged less than 1.5 times.35 114 Platelet transfusions
are rarely required in this case.
Although aprotinin is not a specific antagonist of anti-
platelet agents, it has been shown to decrease postopera-
tive bleeding and transfusion rate in patients undergoing
CABG and treated with clopidogrel during the days pre-
ceding surgery.119
Possible substitutes
An anti-thrombin agent such as a heparin does not mimic
the effect of antiplatelet agents such as clopidogrel or
aspirin. Aspirin substitution by low-molecular weight
heparin does not afford a real protection against the risk of
coronary or stent thrombosis. The infarction and cardiac
complication rates are similar in patients substituted or not
after stopping aspirin.23 121 There are no data to support that
maintenance of aspirin and replacement of clopidogrel by
heparin is an efficient protection in high-risk coronary situ-
ations. Nevertheless, heparin is routinely prescribed as a
substitute because it has been proven efficient in the treat-
ment of unstable angina and non-ST-elevation MI.7
Non-steroidal anti-inflammatory drugs (NSAIDs) as does
ibuprofen or indobufen inhibit COX-1 such as aspirin,37 but
their blocking action on platelet activity is reversible. As
platelet function is completely recovered within 24 h after
NSAID withdrawal, these drugs can be used to maintain an
efficient antiplatelet activity during the week between
aspirin cessation and surgery.98 This might be useful in situ-
ations such as intracranial surgery. Replacing a long-acting
antiplatelet agent such as clopidogrel by a shorter-acting
GP-IIb/IIIa inhibitor such as tirofiban17 or eptifibatid79 has
been suggested empirically as a bridge across the period
between clopidogrel discontinuation and re-initiation.
Unstable coronary syndrome and vital surgery
Antiplatelet drugs are also used in situations where the
patient with unstable coronary syndrome requires vital
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surgery. Depending on how long the surgery can be
delayed, three situations are possible.
† The operation can be delayed for at least 6–8 weeks.
This is enough to perform a PCI with a BMS and allow
4–6 weeks of dual antiplatelet agents therapy. DES is
not an option in this circumstance, because the operation
would be performed during the re-endothelialization
phase, when the risk of stent thrombosis is the highest;
after DES, the delay for elective surgery is 1 yr.39 44
† The surgery can only be delayed for 2–4 weeks. In cases
of extremely unstable coronary flow, very proximal ste-
nosis, and a large area of threatened myocardium, it is
possible to consider a PCI without stenting,21 because
the rate of death and MI of non-cardiac surgery within 2
weeks of balloon angioplasty without stenting is the
same as 3 months later.16 When optimal ‘stent-like’
coronary dilatation is obtained with simple balloon
angioplasty, the MI, repeat revascularization, and death
rates up to 12 months are similar for PCI with or without
BMS.4 Therefore, PCI without stenting may be a safe
means of revascularization for patients who need an
operation with only a short delay.8 20 However, many
cardiologists are reluctant to use this approach and
would rather refrain from any intracoronary intervention.
† The non-cardiac operation must be performed within
24–48 h. The patient should be put on maximal
medical therapy (b-blocker, aspirin, and clopidogrel). It
is useless to perform a coronary angiogram, because the
results will not modify the therapeutic choice. If necess-
ary, a simple transthoracic echocardiography will deter-
mine the ventricular function and rule out associated
valvular disease.
† In all these circumstances, it is safer to operate under
the continued protection of antiplatelet agents and
maximal cardioprotection with b-blocker, aspirin, clopi-
dogrel, and statin.
As yet, these suggestions are not supported by outcome
data of controlled trials with a high level of evidence.
They are gathered from the outcome of different studies
and case reports, many of which have been conducted
outside the surgical setting.
Postoperative PCI
As the greatest risk of ischaemia and infarction occurs
during the first days after surgery, the treatment of chronic
CAD (b-blocker, calcium antagonist, and anti-
hypertensive agent) or unstable coronary syndrome
(aspirin, clopidogrel, and heparin) must be restarted as
soon as possible after the operation. Routine monitoring of
cardiac enzymes is useful to detect silent ischaemia,
which is frequent during the postoperative period, and pre-
dicts long-term mortality.65 ST elevation on the ECG is an
indication for coronary angiogragraphy and PCI. Dilatation
is mandatory, but stenting may be a problem because of
early postoperative acute systemic inflammatory syndrome
and blood hypercoagulability. It is not possible to use
thrombolysis or GP IIb/IIIa inhibitors in the first 24–48 h
after surgery, because of the risk of major bleeding. In
such a case, it may therefore be safer to avoid stenting and
proceed to a simple dilatation.
Conclusions
The present data demonstrate how dependent on antiplate-
let drugs patients with unstable coronary perfusion and
recently implanted stents are. They also demonstrate that
the haemorrhagic risk is usually modest when antiplatelet
therapy is continued throughout surgery. The widespread
use of DES, on the other hand, has shown their risk of late
thrombosis and their dependency on long-term clopido-
grel. Therefore, it seems advisable to change the current
practice of withdrawing antiplatelet drugs before an oper-
ation, except in situations where bleeding might occur in a
closed space or where excessive blood loss is expected.
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